Phenotypic and genotypic analysis of In Vitro-selected artemisinin- resistant progeny of Plasmodium falciparum

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 302-314

  Tucker, Matthew S ^a,b   Mutka, Tina ^a   Sparks, Kansas ^a   Patel, Janus ^a   Kyle, Dennis E ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTELINIC ACID; ARTEMISININ; HYPOXANTHINE; MEFLOQUINE;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CONTROLLED STUDY; GENOTYPE; IN VITRO STUDY; MEROZOITE; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROGENY; REAL TIME POLYMERASE CHAIN REACTION;

ANTIMALARIALS; ARTEMISININS; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ERYTHROCYTES; GENE DOSAGE; GENOTYPE; HUMANS; HYPOXANTHINE; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; MEROZOITES; MICROSCOPY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC CHEMICALS; PARASITIC SENSITIVITY TESTS; PHENOTYPE; PLASMODIUM FALCIPARUM; RECURRENCE;

EID: 84455161818     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05540-11     Document Type: Article

References (58)

1. Afonso A, et al. 2006. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother. 50:480-489. (Pubitemid 43190956)
2. Alker AP, et al. 2007. pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am. J. Trop. Med. Hyg. 76:641-647. (Pubitemid 351627700)
3. Anderson TJ, et al. 2010. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J. Infect. Dis. 201:1326-1330.
4. Bacon DJ, et al. 2007. Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob. Agents Chemother. 51:1172-1178. (Pubitemid 46586790)
5. Balu B, et al. 2009. piggyBac is an effective tool for functional analysis of the Plasmodium falciparum genome. BMC Microbiol. 9:83.
6. Balu B, Singh N, Maher SP, Adams JH. 2010. A genetic screen for attenuated growth identifies genes crucial for intraerythrocytic development of Plasmodium falciparum. PLoS One 5:e13282.
7. Basco LK. 2004. Molecular epidemiology of malaria in Cameroon. XX. Experimental studies on various factors of in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 70:474-480. (Pubitemid 38658140)
8. Basco LK, Le BJ, Rhoades Z, Wilson CM. 1995. Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from sub- Saharan Africa. Mol. Biochem. Parasitol. 74:157-166. (Pubitemid 26024474)
9. Berens RL, Krug EC, Nash PB, Curiel TJ. 1998. Selection and characterization of Toxoplasma gondii mutants resistant to artemisinin. J. Infect. Dis. 177:1128-1131. (Pubitemid 28155178)
10. Bhisutthibhan J, et al. 1998. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J. Biol. Chem. 273:16192-16198. (Pubitemid 28311392)
11. Carrara VI, et al. 2009. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4:e4551.
12. Chavchich M, et al. 2010. Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum. Antimicrob. Agents Chemother. 54:2455-2464.
13. Chawira AN, Warhurst DC, Peters W. 1986. Qinghaosu resistance in rodent malaria. Trans. R. Soc. Trop. Med. Hyg. 80:477-480.
14. Chen N, et al. 2010. Deamplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro. Antimicrob. Agents Chemother. 54: 3395-3401.
15. Chulay JD, Haynes JD, Diggs CL. 1983. Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp. Parasitol. 55:138-146. (Pubitemid 13130670)
16. Codd A, Teuscher F, Kyle DE, Cheng Q, Gatton ML. 2011. Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure. Malar. J. 10:56.
17. Creedon KA, Rathod PK, Wellems TE. 1994. Plasmodium falciparum S-adenosylhomocysteine hydrolase. cDNA identification, predicted protein sequence, and expression in Escherichia coli. J. Biol. Chem. 269: 16364-16370. (Pubitemid 24209335)
18. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. 1979. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16:710-718. (Pubitemid 10082023)
19. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
20. Eckstein-Ludwig U, et al. 2003. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424:957-961. (Pubitemid 37051688)
21. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. 2006. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 36:1427-1441. (Pubitemid 44751746)
22. Heideker J, Lis ET, Romesberg FE. 2007. Phosphatases, DNA damage checkpoints and checkpoint deactivation. Cell Cycle 6:3058-3064.
23. Hoshen MB, Na-Bangchang K, Stein WD, Ginsburg H. 2000. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 121: 237-246.
24. Hunt P, et al. 2010. Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites. BMC Genomics 11:499.
25. Imwong M, et al. 2010. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 54:2886-2892.
26. Inselburg J. 1985. Induction and isolation of artemisinine-resistant mutants of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 34:417-418. (Pubitemid 15041359)
27. Jambou R, et al. 2005. Resistance of Plasmodium falciparum field isolates to in vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366:1960-1963. (Pubitemid 41713986)
28. Koenderink JB, Kavishe RA, Rijpma SR, Russel FG. 2010. The ABCs of multidrug resistance in malaria. Trends Parasitol. 26:440-446.
29. Krishna S, Uhlemann AC, Haynes RK. 2004. Artemisinins: mechanisms of action and potential for resistance. Drug Resist. Update 7:233-244. (Pubitemid 39469096)
30. Lambros C, Vanderberg JP. 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:418-420. (Pubitemid 10222999)
31. Lim P, et al. 2009. pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar. J. 8:11.
32. Looareesuwan S, et al. 1997. Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg. 56:613-617. (Pubitemid 27318581)
33. Makanga M, Bray PG, Horrocks P, Ward SA. 2005. Towards a proteomic definition of CoArtem action in Plasmodium falciparum malaria. Proteomics 5:1849-1858. (Pubitemid 40686230)
34. Mok S, et al. 2011. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 12:391.
35. Nair S, et al. 2007. Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. Mol. Biol. Evol. 24:562-573. (Pubitemid 46204388)
36. Nakazawa S, Maoka T, Uemura H, Ito Y, Kanbara H. 2002. Malaria parasites giving rise to recrudescence in vitro. Antimicrob. Agents Chemother. 46:958-965. (Pubitemid 34260336)
37. Natalang O, et al. 2008. Dynamic RNA profiling in Plasmodium falciparum synchronized blood stages exposed to lethal doses of artesunate.BMC Genomics 9:388.
38. Noedl H, et al. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359:2619-2620.
39. Nosten F, White NJ. 2007. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77:181-192.
40. Peel SA, Bright P, Yount B, Handy J, Baric RS. 1994. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg. 51:648-658. (Pubitemid 24378562)
41. Pickard AL, et al. 2003. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob. Agents Chemother. 47: 2418-2423. (Pubitemid 36919439)
42. Price RN, et al. 2004. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364:438-447. (Pubitemid 39036891)
43. Rathod PK, McErlean T, Lee PC. 1997. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 94: 9389-9393. (Pubitemid 27357839)
44. Reilly HB, Wang H, Steuter JA, Marx AM, Ferdig MT. 2007. Quantitative dissection of clone-specific growth rates in cultured malaria parasites. Int. J. Parasitol. 37:1599-1607. (Pubitemid 47538567)
45. Rodrigues LA, et al. 2010. Experimental evolution of resistance to artemisinin combination therapy results in amplification of the mdr1 gene in a rodent malaria parasite. PLoS One 5:e11593.
46. Teuscher F, et al. 2010. Artemisinin induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J. Infect. Dis. 202:1362-1368.
47. Trager W, Jensen JB. 1976. Human malaria parasites in continuous culture. Science 193:673-675.
48. Uhlemann AC, et al. 2005. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat. Struct. Mol. Biol. 12:628-629.
49. Uhlemann AC, Ramharter M, Lell B, Kremsner PG, Krishna S. 2005. Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J. Infect. Dis. 192:1830-1835. (Pubitemid 41587837)
50. Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S. 2010. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob. Agents Chemother. 54:3842-3852.
51. Wang J, et al. 2010. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 5:e9582.
52. White NJ. 2008. Qinghaosu (artemisinin): the price of success. Science 320:330-334. (Pubitemid 351555649)
53. White NJ, Olliaro P. 1998. Artemisinin and derivatives in the treatment of uncomplicated malaria. Med. Trop. (Madr.). 58:54-56. (In Spanish.) (Pubitemid 128707819)
54. Wilson CM, et al. 1993. Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol. Biochem. Parasitol. 57:151-160.
55. Witkowski B, et al. 2010. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother. 54:1872-1877.
56. Witkowski B, et al. 2010. Plasmodium falciparum isolates with increased pfmdr1 copy number circulate in West Africa. Antimicrob. Agents Chemother. 54:3049-3051.
57. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed. World Health Organization, Geneva, Switzerland. http://www.who .int/malaria/publications/atoz/9789241547925/en/index.html.
58. World Health Organization. 2010. World malaria report 2010. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria /world-malaria-report-2010/en/index.html.